• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Identifying Strategies to Reduce Poor Outcomes in Women With Stroke Spotlight: Women and Heart Disease
Source: Circulation: Cardiovascular Quality and Outcomes - February 21, 2017 Category: Cardiology Authors: Madsen, T. E., Lisabeth, L. D. Tags: Intracranial Hemorrhage, Ischemic Stroke Spotlight: Women and Heart Disease Source Type: research

Riskier Business: Atrial Fibrillation Stroke Prevention in the CHA2DS2-VASc Era Editorials
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2017 Category: Cardiology Authors: Dewland, T. A., Stecker, E. C. Tags: Arrhythmias, Quality and Outcomes, Ischemic Stroke Editorials Source Type: research

Abstract 274: Prevalence of undiagnosed non-valvular atrial fibrillation in the United States Session Title: Poster Session II
Conclusions: Among elderly and working adult U.S. populations, a substantial proportion of individuals with undiagnosed AF have moderate to high risk of stroke. Screening for AF could favorably impact the disease burden.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Turakhia, M. P., Shafrin, J., Bognar, K., Brown, J. B., Trocio, J., Wiederkehr, D., Goldman, D. P. Tags: Session Title: Poster Session II Source Type: research

Abstract 009: The Impact of Participation in a Telestroke Network on In-hospital Mortality in Georgia Session Title: Abstract Oral Session: General
Conclusions: Acute ischemic stroke patients admitted in hospitals participating in a telestroke program had a more pronounced reduction in in-hospital mortality. However, telestroke coverage did not alter the effect of nighttime admission on in-hospital mortality.
Source: Circulation: Cardiovascular Quality and Outcomes - March 31, 2017 Category: Cardiology Authors: Zhang, D., Ido, M. S., Shi, L., Green, D. Tags: Session Title: Abstract Oral Session: General Source Type: research

Abstract 226: Strokes Worse in Women at 24 hours but Severity Reduced in Younger Women With Hormone Therapy Session Title: Poster Session II
Conclusion: Women in this study had more severe 24 hour AIS outcomes than men but this improved with HRT use in women younger than 80 years. This cannot be fully explained by age differences as there could be other underlying factors. Improving 24 hour NIHSS may correctly predict later outcomes following AIS. Further study of HRT use in AIS outcomes is justified.
Source: Circulation: Cardiovascular Quality and Outcomes - March 31, 2017 Category: Cardiology Authors: Brown, A., Onteddu, S., Joiner, R., Benton, T., Culp, W., Lowery, C. Tags: Session Title: Poster Session II Source Type: research

Abstract 169: The Role Of Clinical Prediction Factors On Anticoagulant Selection In Atrial Fibrillation Session Title: Poster Session I
Conclusions: Despite controlling for other patient characteristics, bleeding risk was strongly associated with the selection of a specific anticoagulant. However, the extent of selection explained by predictions of treatment harm was minimal. Providers appear to base anticoagulant selection on factors other than predictions of treatment benefit, which has implications for studying the anticoagulants’ comparative effectiveness.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Lauffenburger, J. Tags: Session Title: Poster Session I Source Type: research

Abstract 276: Asymmetric Dimethylarginine Is A Potential Risk Factor For Transient Ischemic Attack Session Title: Poster Session II
Conclusion: ADMA and VEGF are absolutely increased in TIAs. There is no correlation between ADMA, VEGF, age, sex, blood pressure, glucose and ABCD2 in this small sample size population. But ADMA is probably associated with risk of TIA with no-stroke history. Thus, these findings reveal a possibly new challenging potential of the ADMA and VEGF role in the pathogenesis of TIA.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Zhang, Y., Laskowitz, D., Fan, D. Tags: Session Title: Poster Session II Source Type: research

Abstract 159: Evaluation of Clinical Outcomes among Nonvalvular Atrial Fibrillation Patients Treated With Warfarin or Rivaroxaban Stratified by Presence or Absence of CKD in a Claims Database Session Title: Poster Session II
Conclusions: This study suggests that, in an adult population with NVAF, rivaroxaban-treated patients had fewer ischemic strokes across all patients, including patients with renal impairment. Rivaroxaban-treated patients also had significantly better outcomes for the composite (VTE, MI, or stroke) measure across all groups. Bleeding rates were comparable across all groups.
Source: Circulation: Cardiovascular Quality and Outcomes - March 31, 2017 Category: Cardiology Authors: Weir, M. R., Haskell, L., Berger, J. S., Ashton, V., Laliberte, F., Crivera, C., Brown, K., Lefebvre, P., Schein, J. Tags: Session Title: Poster Session II Source Type: research

Menopause Characteristics, Total Reproductive Years, and Risk of Cardiovascular Disease Among Chinese Women Original Articles
Conclusions— Women with younger age at menopause, longer time since menopause, or fewer total reproductive years had a higher risk of CVD.
Source: Circulation: Cardiovascular Quality and Outcomes - November 8, 2017 Category: Cardiology Authors: Yang, L., Lin, L., Kartsonaki, C., Guo, Y., Chen, Y., Bian, Z., Xie, K., Jin, D., Li, L., Lv, J., Chen, Z., on behalf of the China Kadoorie Biobank Study Collaborative Group Tags: Cardiovascular Disease, Epidemiology, Risk Factors, Women Original Articles Source Type: research

{beta}-Blockers and Cardiovascular Events in Patients With and Without Myocardial Infarction: Post Hoc Analysis From the CHARISMA Trial Original Articles
Conclusions— β-blocker use in patients with prior MI but no heart failure was associated with a lower composite cardiovascular outcome driven by lower risk of recurrent MI with no difference in mortality. However, β-blocker use was not associated with lower cardiovascular events in those without MI, with a suggestion of inferior outcome with regard to stroke risk. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00050817.
Source: Circulation: Cardiovascular Quality and Outcomes - November 18, 2014 Category: Cardiology Authors: Bangalore, S., Bhatt, D. L., Steg, P. G., Weber, M. A., Boden, W. E., Hamm, C. W., Montalescot, G., Hsu, A., Fox, K. A. A., Lincoff, A. M. Tags: Secondary prevention Original Articles Source Type: research

Abstract 144: Cost of Cardiovascular Disease Episodes among Patients with Hypertension Session Title: Poster Session I
Conclusions: Cost estimates of CVD episodes among hypertensive patients are consistent with results from the scarce literature in this area. Moreover, our study finds evidence of increased medical resource utilization weeks before the recording of the CVD episode. Omitting these pre-event costs leads to an underestimate of the true costs of CVD.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Arrieta, A., Qiao, N., Woods, J. R., Jay, S. J., Veledar, E., Nasir, K. Tags: Session Title: Poster Session I Source Type: research

Abstract 203: Outcomes Comparison of Low Risk Medical and Surgical Patients Treated with Unfractionated Heparin vs. Enoxaparin Poster Session II
Conclusions: In low-risk medical and general surgical patients, UFH was as effective as enoxaparin in the prevention of thromboembolic events, with no difference in the incidence of HIT. When compared to UFH, enoxaparin was associated with lower MI and mortality rates, and shorter LOS and ICU LOS, at the expense of higher rates of stroke and TIA. Enoxaparin was associated with lower total inpatient costs than UFH.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Corbelli, J., Zammit, K., Griffiths, B., Ma, C., Tung, Y., Graves, C., Genena, D., Boyd, D., Meyer, F., Arbogast, P., Bourji, M. Tags: Poster Session II Source Type: research

Abstract 277: Conveying Risks and Benefits of rt-PA: the Eyes Have It Session Title: Poster Session II
Conclusions: Our preliminary data suggest that stacked bar graphs facilitate better understanding of the risks and benefits of rt-PA in acute IS. Presenting data in this format could better engage patients and families in making treatment decisions in the setting of IS.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Decker, C., Poirier, M. W., Chhatriwalla, E., Gialde, E., Spertus, J. A., Mayhugh, T. M., Schleicher, K. M., McDowd, J. M. Tags: Session Title: Poster Session II Source Type: research

Abstract 146: Clinical and Economic Consequences of Statin Intolerance in the U.S.: Results from an Integrated Health System Session Title: Poster Session I
Conclusion: While the majority of SI patients were on a statin, SI patients demonstrate a higher risk of some cardiovascular events; incur higher healthcare costs; and difficulty reaching LDL-C goals compared to patients without SI. Alternative treatment strategies are needed to better serve this at-risk patient population.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Sanchez, R. J., Graham, J. H., Evans, M. A., Mallya, U. G., Panaccio, M. P., Steinhubl, S. R. Tags: Session Title: Poster Session I Source Type: research

Abstract 372: Health Outcomes Associated With Triple Antiplatelet Therapy for the Secondary Prevention of Atherothrombotic Events Session Title: Poster Session III
Vorapaxar is a protease-activated receptor-1 (PAR-1) antagonist indicated for the reduction of atherothrombotic cardiovascular (CV) events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD), based on the findings of the TRA 2°P-TIMI 50 trial for patients without a history of stroke or transient ischemic attack. This analysis evaluated the health outcomes of triple antiplatelet therapy with vorapaxar when added to a standard care regimen of clopidogrel plus aspirin (ASA) in comparison with standard care alone, for patients without a history of transient ischemic attack or ...
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Ozer-Stillman, I., Whalen, J. D., Bash, L. D., Oguz, M., Du, M., Singhal, P. K., Davies, G. M. Tags: Session Title: Poster Session III Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12